These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 25797360)

  • 1. Biosynthetically engineered lipopolysaccharide as vaccine adjuvant.
    Zariri A; van der Ley P
    Expert Rev Vaccines; 2015 Jun; 14(6):861-76. PubMed ID: 25797360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Supplementation of whole-cell pertussis vaccines with lipopolysaccharide analogs: modification of vaccine-induced immune responses.
    Geurtsen J; Fransen F; Vandebriel RJ; Gremmer ER; de la Fonteyne-Blankestijn LJ; Kuipers B; Tommassen J; van der Ley P
    Vaccine; 2008 Feb; 26(7):899-906. PubMed ID: 18207288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modification of lipid A biosynthesis in Neisseria meningitidis lpxL mutants: influence on lipopolysaccharide structure, toxicity, and adjuvant activity.
    van der Ley P; Steeghs L; Hamstra HJ; ten Hove J; Zomer B; van Alphen L
    Infect Immun; 2001 Oct; 69(10):5981-90. PubMed ID: 11553534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved immunogenicity of tetanus toxoid by Brucella abortus S19 LPS adjuvant.
    Mohammadi M; Kianmehr Z; Kaboudanian Ardestani S; Gharegozlou B
    Iran J Immunol; 2014 Sep; 11(3):189-99. PubMed ID: 25266004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant effect of bacterial outer membrane vesicles with penta-acylated lipopolysaccharide on antigen-specific T cell priming.
    Lee DH; Kim SH; Kang W; Choi YS; Lee SH; Lee SR; You S; Lee HK; Chang KT; Shin EC
    Vaccine; 2011 Oct; 29(46):8293-301. PubMed ID: 21893142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvants containing natural and synthetic Toll-like receptor 4 ligands.
    Ireton GC; Reed SG
    Expert Rev Vaccines; 2013 Jul; 12(7):793-807. PubMed ID: 23885824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Active immunization with a detoxified endotoxin vaccine protects against lethal polymicrobial sepsis: its use with CpG adjuvant and potential mechanisms.
    Opal SM; Palardy JE; Chen WH; Parejo NA; Bhattacharjee AK; Cross AS
    J Infect Dis; 2005 Dec; 192(12):2074-80. PubMed ID: 16288370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipopolysaccharide, lipid A, and liposomes containing lipid A as immunologic adjuvants.
    Alving CR
    Immunobiology; 1993 Apr; 187(3-5):430-46. PubMed ID: 8330907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Next-generation outer membrane vesicle vaccines against Neisseria meningitidis based on nontoxic LPS mutants.
    van der Ley P; van den Dobbelsteen G
    Hum Vaccin; 2011 Aug; 7(8):886-90. PubMed ID: 21785281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Well-defined and potent liposomal meningococcal B vaccines adjuvated with LPS derivatives.
    Arigita C; Luijkx T; Jiskoot W; Poelen M; Hennink WE; Crommelin DJ; Ley Pv; Els Cv; Kersten GF
    Vaccine; 2005 Oct; 23(43):5091-8. PubMed ID: 15993990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipopolysaccharide: Biosynthetic pathway and structure modification.
    Wang X; Quinn PJ
    Prog Lipid Res; 2010 Apr; 49(2):97-107. PubMed ID: 19815028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipopolysaccharide analogs improve efficacy of acellular pertussis vaccine and reduce type I hypersensitivity in mice.
    Geurtsen J; Banus HA; Gremmer ER; Ferguson H; de la Fonteyne-Blankestijn LJ; Vermeulen JP; Dormans JA; Tommassen J; van der Ley P; Mooi FR; Vandebriel RJ
    Clin Vaccine Immunol; 2007 Jul; 14(7):821-9. PubMed ID: 17494641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipopolysaccharide contamination in intradermal DNA vaccination: toxic impurity or adjuvant?
    van den Berg JH; Quaak SG; Beijnen JH; Hennink WE; Storm G; Schumacher TN; Haanen JB; Nuijen B
    Int J Pharm; 2010 May; 390(1):32-6. PubMed ID: 19576975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of Brucella abortus lipopolysaccharide as an adjuvant for tuberculin PPD.
    Jamalan M; Ardestani SK; Zeinali M; Mosaveri N; Mohammad Taheri M
    Biologicals; 2011 Jan; 39(1):23-8. PubMed ID: 20965746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Chemical structure and biosynthesis of lipopolysaccharide--important component of the cell envelope of Gram-negative bacteria].
    Kaszowska M
    Postepy Hig Med Dosw (Online); 2004; 58():333-42. PubMed ID: 15459551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Designer outer membrane vesicles as immunomodulatory systems - Reprogramming bacteria for vaccine delivery.
    Gnopo YMD; Watkins HC; Stevenson TC; DeLisa MP; Putnam D
    Adv Drug Deliv Rev; 2017 May; 114():132-142. PubMed ID: 28501509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diversity of endotoxin and its impact on pathogenesis.
    Trent MS; Stead CM; Tran AX; Hankins JV
    J Endotoxin Res; 2006; 12(4):205-23. PubMed ID: 16953973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In planta production of plant-derived and non-plant-derived adjuvants.
    Granell A; Fernández del-Carmen A; Orzáez D
    Expert Rev Vaccines; 2010 Aug; 9(8):843-58. PubMed ID: 20673009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of the IgG subclass responses to lipopolysaccharide by bacterial membrane components: differential adjuvant effects produced by primary and secondary stimulation.
    Karch H; Nixdorff K
    J Immunol; 1983 Jul; 131(1):6-8. PubMed ID: 6345666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of nine candidate DTP-vaccines with reduced amount of antigen and/or without adjuvant as a fourth (booster-) dose in the second year of life.
    Knuf M; Habermehl P; Faber J; Bock HL; Sänger R; Bogaerts H; Clemens R; Schuind A; du Prel JB; Schmitt HJ
    Vaccine; 2006 Jul; 24(27-28):5627-36. PubMed ID: 16740348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.